Related references
Note: Only part of the references are listed.Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab
Anthony J. Ocon et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2023)
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
Quentin Moyon et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Manuel Francisco Ugarte-Gil et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
Jade Heitz et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)
B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab
Sarah Jinich et al.
ARTHRITIS & RHEUMATOLOGY (2022)
B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab
Ana-Luisa Stefanski et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
Ingrid Jyssum et al.
LANCET RHEUMATOLOGY (2022)
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
Kathleen M. Andersen et al.
LANCET RHEUMATOLOGY (2022)
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients
Martina Fabris et al.
JOURNAL OF AUTOIMMUNITY (2022)
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4
Jeffrey R. Curtis et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Yemil Atisha-Fregoso et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
Matthias B. Moor et al.
LANCET RHEUMATOLOGY (2021)
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
Jerome Avouac et al.
LANCET RHEUMATOLOGY (2021)
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Anja Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers
Christian Irsara et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
Qiu-Yan Xu et al.
FRONTIERS IN IMMUNOLOGY (2021)
CD19+IgD+CD27-Naive B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients
Eduard Schulz et al.
FRONTIERS IN IMMUNOLOGY (2021)
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
Jose Maria Alvaro Gracia et al.
RMD OPEN (2021)
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study
Parakkal Deepak et al.
ANNALS OF INTERNAL MEDICINE (2021)
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
Marcia A. Friedman et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Victoria Furer et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Daniel Mrak et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer et al.
ARTHRITIS & RHEUMATOLOGY (2019)